Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03560882 · ClinicalTrials.gov registry record · Phase 1
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
A Phase 1 study of Cancer and Acute Myeloid Leukemia, sponsored by Joaquina Baranda.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03560882: Active Phase 1 study of Cancer and Acute Myeloid Leukemia, sponsored by Joaquina Baranda.
NCT03560882 is a Phase 1 study of Cancer and Acute Myeloid Leukemia that is active but no longer recruiting, run by Joaquina Baranda. The registered enrollment target is 50 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03560882, a Phase 1 study of Cancer and Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Joaquina Baranda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in malignant diseases (solid tumor and relapsed Acute Myeloid Leukemia (AML)).
Primary Outcome
Measured by immunohistochemistry (IHC) staining. Reported as overall percent difference in the level of conformation mutant p53.
Conditions Studied
Interventions
- DRUG Atorvastatin
Study Locations (1)
Kansas
- University of Kansas Cancer Center - CRC - Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-07-19 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 1 |
What the registry record for NCT03560882 still lists
NCT03560882 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin is the first listed.
NCT03560882 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03560882 about?
NCT03560882 is a clinical study titled "A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies". This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in malignant diseases (solid tumor and relapsed Acute Myeloid Leukemia (AML)).
What is the current status of trial NCT03560882?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2018-07-19. Estimated completion is 2025-08-01.
What conditions does trial NCT03560882 study?
This clinical trial studies the following conditions: Cancer, Acute Myeloid Leukemia, Solid Tumor, Myelodysplastic Syndromes, Relapsed Hematologic Malignancy.
What interventions are being tested in trial NCT03560882?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT03560882?
This trial is sponsored by Joaquina Baranda, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03560882 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03560882's enrollment target sits among peer trials
50 422nd of 615 higher than 179 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI